Maria Gemelli
@MariaGemelli89
Followers
40
Following
359
Media
8
Statuses
57
Joined May 2022
CIOT 2025 just concluded in Venice: top-notch content and inspiring discussions. Thank you all — see you next year in Palermo! #Oncology #LungCancer #CIOT
0
0
0
RT @StephenVLiu: Dr. @TonyMok9 discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is pati….
0
13
0
📢 Now Online! . Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC. Grateful to all the co-authors. 🔗 Full article here: #NSCLC #immunotherapy #lungcancer
3
6
14
Exciting days at the EORTC Lung Cancer Group Spring Meeting!.Innovative proposals, great teamwork, and strong support for young researchers. Happy to be part of this!.#EORTC #LungCancer
0
0
2
RT @JordiRemon: Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an….
0
12
0
Wrapping up my ESMO experience and heading home. It’s been a whirlwind of emotions…. the first time for me as a speaker, exciting new data, and the pleasure of reconnecting with colleagues old and new. Thank you for the incredible moments! #ESMO2024
0
1
18
RT @IASLC: A friendly competition among the 2024 IASLC Academy class will culminate at #WCLC24. Participants Sally Lau, MD, and @MariaGemel….
ilcn.org
After a successful inaugural year in 2023, participants have once again crafted case summaries, and WCLC 2024 attendees will help choose the winning cases.
0
3
0
RT @BenjaminBesseMD: Stop pembro after 2 years?. In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation bey….
0
90
0
RT @StephenVLiu: Multidisciplinary consensus statement & practical recommendations on neoadjuvant & adjuvant therapy for early stage resect….
jto.org
Advances in the multidisciplinary care of early stage resectable NSCLC (rNSCLC) are emerging at an unprecedented pace. Numerous phase 3 trials produced results that have transformed patient outcomes...
0
15
0
RT @lungoncdoc: Engaging discussions this morning on our @IASLC Academy projects!. Great to have Academy co-chair @ChristianRolfo join us a….
0
6
0
RT @filippog92: @DoctorJSpicer @MThoracics Thrilled and proud to be working with you @DoctorJSpicer, @LyndonCWalsh @MThoracics! Excitedly a….
0
4
0
RT @BenjaminBesseMD: Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+….
cell.com
Efficacy of CAR T cell therapy and immune checkpoint blockade in cancer can be improved by adjusting the time of treatment during the day due to rhythmic infiltration and function of T cells regula...
0
34
0
RT @DrJNaidoo: Ph III CM77T trial @NEJM: Periop Nivo in Stage IIA-IIIB NSCLC:. - neoadj nivo+chemo x 4 + 1yr adj nivo v neoadj chemo x 4 +….
nejm.org
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj...
0
13
0
RT @StephenVLiu: US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC….
0
32
0
RT @PrelajArsela: On 10 May at @IstTumori and online for the second edition of the "AI for Oncology" conference, we will explore how AI is….
0
14
0
RT @NEJM: In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free….
0
76
0
RT @DrJNaidoo: 🔥Big News. Press Release: Ph III ADRIATIC Trial meets OS & PFS Endpoints for Durva v Placebo in Limited Stage SCLC:. - 730pt….
0
60
0